SCIENCE: An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Speech sensitive to treatment response

 

Click here for more details.

Tags: , , ,

Related Post

Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program

  • Posted on 14 September, 2023
    Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
    Read more

    Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

    • Posted on 11 August, 2023
      Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead...
      Read more

      Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise

      • Posted on 27 April, 2023
        MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...
        Read more